within Pharmacolibrary.Drugs.ATC.V;

model V09AX05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.000175,
    adminDuration  = 600,
    adminMass      = 370 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00445,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.013300000000000001,
    k12             = 43.2,
    k21             = 43.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09AX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Florbetapir (18F) is a radioactive diagnostic agent, a fluorine-18 labeled PET radiotracer used in positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. It is FDA approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects, both male and female, typical for adults undergoing amyloid PET imaging.</p><h4>References</h4><ol><li><p>Lowe, SL, et al., &amp; Sims, JR (2021). Donanemab (LY3002813) Phase 1b Study in Alzheimer&#x27;s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. <i>The journal of prevention of Alzheimer&#x27;s disease</i> 8(4) 414–424. DOI:<a href=\"https://doi.org/10.14283/jpad.2021.56\">10.14283/jpad.2021.56</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34585215/\">https://pubmed.ncbi.nlm.nih.gov/34585215</a></p></li><li><p>Sundaram, GSM, et al., &amp; Sharma, V (2020). Fluselenamyl: Evaluation of radiation dosimetry in mice and pharmacokinetics in brains of non-human primate. <i>Nuclear medicine and biology</i> 82-83 33–40. DOI:<a href=\"https://doi.org/10.1016/j.nucmedbio.2019.10.004\">10.1016/j.nucmedbio.2019.10.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31891882/\">https://pubmed.ncbi.nlm.nih.gov/31891882</a></p></li><li><p>Siemers, E, et al., &amp; Barton, R (2023). ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. <i>The journal of prevention of Alzheimer&#x27;s disease</i> 10(1) 19–24. DOI:<a href=\"https://doi.org/10.14283/jpad.2022.93\">10.14283/jpad.2022.93</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36641606/\">https://pubmed.ncbi.nlm.nih.gov/36641606</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09AX05;
